Alirocumab and Lipid Levels, Inflammatory Biomarkers, Metabolomics, and Safety in Patients Receiving Maintenance Dialysis: The ALIrocumab in DIALysis Study (A Phase 3 Trial to Evaluate the Efficacy and Safety of Biweekly Alirocumab in Patients on a Stable Dialysis Regimen)

RATIONALE & OBJECTIVE: The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor alirocumab is used in the general population to treat dyslipidemia, but little is known about the effects of alirocumab on lipid levels, biomarkers, the metabolome, and safety in individuals receiving main...

Descripción completa

Detalles Bibliográficos
Autores principales: East, Cara, Bass, Kyle, Mehta, Ankit, Rahimighazikalayed, Gelareh, Zurawski, Sandy, Bottiglieri, Teodoro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9253651/
https://www.ncbi.nlm.nih.gov/pubmed/35801187
http://dx.doi.org/10.1016/j.xkme.2022.100483

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9253651/
https://www.ncbi.nlm.nih.gov/pubmed/35801187
http://dx.doi.org/10.1016/j.xkme.2022.100483

Ejemplares similares